Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients

Journal of Parkinson's Disease

Volumn 3, Issue 2, 2013, Pages 145-152

  Dzamko, Nicolas ^a,b   Chua, Germaine ^a   Ranola, Madelaine ^b   Rowe, Dominic B ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

antibody. LRRK2; immunity; inflammation; Kinase; lymphocyte; monocyte; neurodegeneration; Parkinson's disease; phosphorylation

Indexed keywords

GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; SERINE;

AGED; ARTICLE; CELL VIABILITY; CENTRIFUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; HUMAN; IDIOPATHIC DISEASE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; PARKINSON DISEASE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY;

AGED; FEMALE; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 84880218192     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130174     Document Type: Article

References (41)

1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de SilvaR, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, & Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600.
2. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, & Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607.
3. Paisan-Ruiz C, Nath P, Washecka N, Gibbs JR, & Singleton AB (2008) Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls. Hum Mutat 29, 485-490.
4. Paisan-Ruiz C (2009) LRRK2 gene variation and its contribution to Parkinson disease. Hum Mutat 30, 1153-1160.
5. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, & Dawson TM (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad SciUS A 102, 16842-16847.
6. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, & Alessi DR (2007) LRRK2 phosphorylates moesin at threonine-558: Characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405, 307-317.
7. Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, & Gray NS (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 7, 203-205.
8. Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, Drewes G, Bantscheff M, Bard F, Dawson TM, HopfC(2011) Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinson's Disease-Related Toxicity in Human Neurons. ACS Chem Biol 6, 1021-1028.
9. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, & Cookson MR (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357, 668-671.
10. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, & Yue Z (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103, 238-247.
11. Daniels V, Vancraenenbroeck R, Law BM, Greggio E, Lobbestael E, Gao F, De Maeyer M, Cookson MR, Harvey K, Baekelandt V, & Taymans JM (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J Neurochem 116, 304-315.
12. Nichols RJ, Dzamko N,Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, & Alessi DR (2010) 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J 430, 393-404.
13. Li X, Wang QJ, Pan N, Lee S, Zhao Y, Chait BT, & Yue Z (2011) Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One 6, e17153.
14. Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ (2010) Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 430, 405-413.
15. Gloeckner CJ, Boldt K, von Zweydorf F, Helm S, Wiesent L, Sarioglu H, & Ueffing M (2010) Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2. J Proteome Res 9, 1738-1745.
16. Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, & Podolsky DK (2011) LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol 185, 5577-5585.
17. Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C,&Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 6, e21519.
18. Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G,Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, & Schlossmacher MG (2011) Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 118, 795-808.
19. Brodacki B, Staszewski J, Toczylowska B, Kozlowska E, Drela N, Chalimoniuk M, & Stepien A (2008) Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441, 158-162.
20. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, & Park DS (2007) Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 27, 3328-3337.
21. Moehle MS, Webber PJ, Tse T, Sukar N, Standaert DG, DeSilva TM, Cowell RM, &West AB (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32, 1602-1611.
22. Liu Z, Lee J, Krummey S, LuW, Cai H,&Lenardo MJ (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12, 1063-1070.
23. Dzamko N, Inesta-Vaquera F, Zhang J, Xie C, Cai H, Arthur S, Tan L, Choi H, Gray NS, Cohen P, Pedrioli P, Clark K, & Alessi DR (2012) The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. Plos One 7, e39132.
24. Hoehn MM, Yahr MD (1967) Parkinsonism: Onset, progression and mortality. Neurology 17, 427-442.
25. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J,Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, & LaPelle N (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23, 2129-2170.
26. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, & Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25, 2649-2653.
27. Hashad DI, Abou-Zeid AA, Achmawy GA, Allah HM, & Saad MA (2011) G2019S mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson's disease. Genet Test Mol Biomarkers 15, 861-866.
28. HuangY, Halliday GM,Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn PA, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, & Sue CM (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord 22, 982-989.
29. Schneider CA, Rasband WS, & Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675.
30. Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P,KeeK, Schule B, Dolmetsch RE, LangstonW, Palmer TD,&Pera RR (2011) LRRK2 mutant iPSC-derivedDAneurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8, 267-280.
31. Cooper O, Seo H, Andrabi S, Guardia-Laguarta C, Graziotto J, Sunberg M, McLean JR, Carrillo-Reid L, Xie Z, Osborn T, Hargus G, Deleidi M, Lawson T, Bogetofte H, Perez-Tores E, Clark L, Moskowitz C, Mazzulli J, Chen L, Volpicelli-Dalay L, Romero N, Jiang H, Uitti RJ, Huang Z, Opala G, Scarffe LA, Dawson VL, Klein C, Feng J, Ross OA, Trojanowski JQ, Lee VM,Marder K, Surmeier DJ, Wszolek ZK, Przedborski S, Krainc D, Dawson TM, & Isacson O (2012) Pharmacological rescue of mitochondrial deficits in iPSCderived neural cells from patients with familial Parkinson's disease. Sci Transl Med 4, 141ra190.
32. Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, Yates J, Esteban CR, Sancho-Martinez I, & Izpisua Belmonte JC (2012) Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491, 603-607
33. Papkovskaia TD, Chau KY, Inesta-Vaquera F, Papkovsky DB, Healy DG, Nishio K, Staddon J, Duchen MR, Hardy J, Schapira AH, & Cooper JM (2012) G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization. Hum Mol Genet 21, 4201-4213.
34. Yao C, Johnson WM, Gao Y, Wang W, Zhang J, Deak M, Alessi DR, Zhu X, Mieyal JJ, Roder H,Wilson-Delfosse AL, &Chen SG (2012) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. Hum Mol Genet 22, 328-344.
35. Liu Z, Hamamichi S, Lee BD, Yang D, Ray A, Caldwell GA, Caldwell KA, Dawson TM, Smith WW, & Dawson VL (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 20, 3933-3942.
36. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, & Cookson MR (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23, 329-341.
37. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, deVos M,Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, & Daly MJ (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40, 955-962.
38. Torkvist L, Halfvarson J, Ong RT, Lordal M, Sjoqvist U, Bresso F, Bjork J, Befrits R, Lofberg R, Blom J, Carlson M, Padyukov L, D'Amato, Seielstad M, & Pettersson S (2010) Analysis of 39 Crohn's disease risk loci in Swedish inflammatory bowel disease patients. Inflamm Bowel Dis 16, 907-909.
39. Orr CF, Rowe DB, & Halliday GM (2002) An inflammatory review of Parkinson's disease. Prog Neurobiol 68, 325-340.
40. Collins LM, Toulouse A, Connor TJ, & Nolan YM (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62, 2154-2168.
41. Auffray C, SiewekeMH,&Geissmann F (2009) Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27, 669-692.